Application of Chinese medicine composition in preparing medicine for preventing and treating gouty arthritis
The preparation of Wuling Capsules by using traditional Chinese medicine compositions of Bupleurum, Ganoderma lucidum, Salvia miltiorrhiza and Schisandra chinensis solved the problem of major side effects of existing drugs, significantly improved joint swelling, inflammatory factor levels and pain in gouty arthritis, and provided a A safe and effective treatment approach.
Patent Information
- Application Number
- CN202311181890.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-09-13
AI Technical Summary
Existing drugs used to treat gouty arthritis, such as colchicine, have obvious side effects and are not safe and effective in treatment, resulting in the need to find safer and more effective drug solutions.
Using a traditional Chinese medicine composition, including Bupleurum, Ganoderma lucidum, Salvia miltiorrhiza and Schisandra chinensis, Wuling Capsules are prepared by optimizing the ratio, which are used to prevent and treat gouty arthritis, improve joint swelling, anti-inflammatory and analgesic.
Wuling Capsules significantly reduced the joint swelling index and inflammatory factor levels in gouty arthritis patients, relieved pain, and improved the inflammatory infiltration of joint synovial tissue, demonstrating the anti-inflammatory and analgesic effects on gouty arthritis. .
Smart Images

Figure HDA0004447596050000011 
Figure HDA0004447596050000012 
Figure HDA0004447596050000021
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicines, and in particular to application of a traditional Chinese medicine composition in preparing medicines for preventing and treating gouty arthritis. Background Art
[0002] Gouty arthritis is caused by the deposition of urate in the joint capsule, bursa, cartilage, bone and other tissues, which causes lesions and inflammatory reactions. It is more common in the metatarsophalangeal joint of the big toe, and can also occur in other larger joints, especially the ankle and foot joints. The tissues around the joints are obviously swollen, hot, red and tender. In gout, the sodium urate crystals released by the synovial tissue and articular cartilage are swallowed by the white blood cells in the synovial fluid, and the white blood cells break down and release proteases and inflammatory factors into the synovial fluid. With the gradual increase in the incidence of gout, it has brought great pain and inconvenience to people's lives. Gout is significantly associated with diabetes, cardiovascular disease and kidney disease, but the types of uric acid-lowering drugs currently used in clinical practice are limited and have obvious adverse reactions.
[0003] Xanthine oxidase (XOD) is a very important enzyme in uric acid metabolism in the body. It catalyzes the oxidation of hypoxanthine to xanthine, and further catalyzes the oxidation of xanthine to uric acid. When the uric acid concentration is too high, it will lead to hyperuricemia, which can further cause the onset of gout.
[0004] At present, colchicine can be used for acute attacks of gouty arthritis, which can be very effective in anti-inflammatory and analgesic, and can achieve the effect of treating redness, swelling, heat and pain in joints in a short period of time. At the same time, it can also be used to prevent acute attacks of gouty arthritis when uric acid-lowering treatment begins in the remission period. However, colchicine has obvious side effects, such as diarrhea, and some patients even experience severe dehydration, electrolyte imbalance, hair loss, rash, and liver damage. Some patients may also experience muscle and joint manifestations, such as muscle weakness, numbness, tingling, or elevated muscle enzymes. Some patients may also experience shock symptoms after taking colchicine. Therefore, it is necessary to find a safer and more effective drug to prevent and treat gouty arthritis. Summary of the invention
[0005] In view of this, the technical problem to be solved by the present invention is to provide an application of a Chinese medicine composition in the preparation of a drug for preventing and treating gouty arthritis, thereby providing a new treatment approach for gouty arthritis.
[0006] The present invention provides an application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating gouty arthritis;
[0007] The traditional Chinese medicine composition comprises the following active ingredients: bupleurum root, ganoderma lucidum, salvia miltiorrhiza and schisandra chinensis.
[0008] The ratio of each component of the above active ingredient is preferably as follows:
[0009] 200-350 parts by weight of Bupleurum Root; 150-200 parts by weight of Ganoderma Lucidum; 300-400 parts by weight of Salvia Miltiorrhiza; 300-400 parts by weight of Schisandra Chinensis Fruit.
[0010] Further preferably, the ratio of each component of the above active ingredient is preferably as follows:
[0011] 340-350 parts by weight of Bupleurum, 170-180 parts by weight of Ganoderma Lucidum, 340-350 parts by weight of Salvia Miltiorrhiza, and 340-350 parts by weight of Schisandra Chinensis.
[0012] In some specific embodiments of the present invention, the ratio of each component of the above active ingredients is preferably as follows:
[0013] 342 parts by weight of Bupleurum Root, 173 parts by weight of Ganoderma Lucidum, 342 parts by weight of Salvia miltiorrhiza, and 342 parts by weight of Schisandra Chinensis.
[0014] The present invention has no particular limitation on the dosage form of the above-mentioned Chinese medicine composition, including but not limited to tablets, capsules, powders, oral liquids, pills and other conventional dosage forms in the art.
[0015] Optionally, the Chinese medicine composition is Wuling Capsule.
[0016] In the present invention, the prevention and treatment include improving joint swelling, anti-inflammation, analgesia and / or improving joint pathological conditions.
[0017] Optionally, the improving joint swelling includes reducing the joint swelling index and / or reducing the joint circumference.
[0018] Optionally, the anti-inflammatory effect includes: reducing the level of inflammatory factors in the serum of patients with gouty arthritis.
[0019] Optionally, the inflammatory factors include IL-1β and TNF-α.
[0020] Optionally, the analgesia includes reducing one or more of swelling, fever, redness, and tenderness in the joints and surrounding tissues of patients with gouty arthritis.
[0021] Optionally, the improvement of joint pathological state includes: reducing the inflammatory infiltration of the synovial membrane and surrounding tissues of patients with gouty arthritis.
[0022] Optionally, the gouty arthritis is acute gouty arthritis.
[0023] Compared with the prior art, the present invention provides an application of a Chinese medicine composition in the preparation of a drug for preventing and treating gouty arthritis; the Chinese medicine composition comprises the following active ingredients: bupleurum, ganoderma lucidum, salvia miltiorrhiza, and schisandra chinensis. The present invention verifies through animal experiments that the above-mentioned Chinese medicine composition has a certain inhibitory effect on inflammatory factors in serum and has a relieving effect on the pain of rats with acute gouty arthritis. It can improve the joint swelling of rats with acute gouty arthritis, significantly reduce the level of inflammatory factors in rat serum, relieve the pain of rats, and improve the infiltration of inflammatory cells in the synovial tissue of the joints, indicating that the above-mentioned Chinese medicine composition has a certain anti-inflammatory and analgesic effect on acute gouty arthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a picture of sodium monourate crystals;
[0025] Figure 2 The effect of Wuling capsule on joint circumference and joint swelling in rats with acute gouty arthritis (n=6);
[0026] Figure 3 The effect of Wuling capsule on the levels of IL-1β and TNF-α in the serum of rats with acute gouty arthritis (n=3);
[0027] Figure 4 The effect of Wuling capsule on pain perception in rats with acute gouty arthritis (n=3);
[0028] Figure 5 This is the effect of Wuling Capsule on ankle joint pathology in rats with acute gouty arthritis (n=3). DETAILED DESCRIPTION
[0029] To further illustrate the present invention, the application of the Chinese medicine composition provided by the present invention in the preparation of a medicine for preventing and treating gouty arthritis is described in detail below in conjunction with examples.
[0030] Example 1 Evaluation of the effect of Wuling Capsule on acute gouty arthritis in rats
[0031] 1 Materials
[0032] 1.1 Trial Drugs
[0033] Wuling capsule powder (batch number: 220812), Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. 36 clean-grade male SD rats, weighing (220±20) g, were purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0034] 1.2 Reagents
[0035] Anhydrous ethanol, xylene, neutral gum (batch number 100092683, 10023418, 10004160) were from Sinopharm Chemical Reagent Co., Ltd., HE staining solution set (batch number G1003) was from Servicebio. Sodium urate (MSU: batch number, 102450412) was from Sigma.
[0036] 1.3 Instruments
[0037] KW-11A bipedal balance pain meter (Nanjing Calvin Biotechnology Co., Ltd.), Thermo an GO 1510 full-wavelength microplate reader, Micro17R microcentrifuge, Thermo Scientific Forma 900 Series-80°C ultra-low temperature refrigerator (Thermo Fisher Scientific), IX73 inverted microscope (Olympus Micro-Optics Technology Co., Ltd.), ME204 / 02 electronic balance (Mettler-Toledo Co., Ltd.). YSL-7C foot volume meter (Jinan Yiyanyan Technology Development Co., Ltd., Shandong Medical College).
[0038] 2 Methods
[0039] 2.1 Preparation of sodium monourate crystals
[0040] Weigh 800 mg of sodium urate and dissolve it in 5 mL of 1 mol / L NaOH solution, add it to 155 mL of sterile 0.5% sodium chloride solution, heat and stir to completely dissolve, cool naturally and adjust the pH to 7.2 with 1 mol / L HCl, and keep it at room temperature overnight. The next day, centrifuge and collect the precipitate, dry it at 70°C, collect the monosodium urate crystals (MSU) and store them at 4°C for later use.
[0041] 2.2 Establishment and administration of acute gouty arthritis rat model
[0042] Sodium monourate crystals were ground into powder using a mortar and pestle, and a 25 mg / mL sodium monourate crystal suspension was prepared using normal saline. After one week of adaptive feeding, the rats were injected with the pretreated sodium monourate crystal suspension into the ankle joint cavity, and a single intra-articular injection of MSU 0.2 mL was given to establish an acute gouty arthritis model in rats.
[0043] After intra-articular injection of pretreated sodium monourate crystal suspension, the blank group and model group were given the same dose of pure water every day, and Wuling Capsule was administered at the clinical dose of 5.5g / 70kg, which was converted into the rat dose, including Wuling Capsule low-dose group (0.25g / kg), Wuling Capsule medium-dose group (0.5g / kg), Wuling Capsule high-dose group (1.0g / kg), and colchicine group (0.3mg / kg).
[0044] 2.3 Detection of joint circumference and swelling in rats with acute gouty arthritis
[0045] The ankle circumference of the rats was measured by thread application method at 0h before modeling and 6, 12, 24, and 48h after modeling, and the ankle volume of the rats was measured using a toe swelling meter. Ankle swelling degree (%) = (dt-dn) / dn*100%, where dt: ankle circumference of the right hind paw after modeling, dn: ankle circumference of the right hind paw before modeling. Toe swelling degree (%) = (Vt-Vn) / Vn*100%, where Vt: right hind paw volume after modeling, Vn: right hind paw volume before modeling.
[0046] 2.4 Evaluation of pain behavior in rats with acute gouty arthritis
[0047] The weight distribution of the rat's hind paws was measured using bipedal balance analgesia. During the test, the rat stood in the chamber with the front paws on the inclined plane and the hind paws on two different transducer planes. The weight distribution test was performed when the rats were in a quiet state. Three measurements were performed randomly on each group of rats, and the test duration was set to 9 seconds. The results are shown as the ratio of the weight of the injected / operated (right) hind limb to the weight of the contralateral hind limb (left).
[0048] 2.5 Joint tissue sections of rats with acute gouty arthritis
[0049] The rat ankle joint tissue was cleaned and sliced with a slicer. The tissue was dewaxed for 15 minutes using xylene I and xylene II, and rehydrated with gradient ethanol from high to low for 5 minutes. The slices were then stained with hematoxylin stain for 3-5 minutes, rinsed with pure water, differentiated with differentiation solution, rinsed with pure water, and then stained with eosin for 4 minutes. The tissue was reblued with blueing solution, and then dehydrated with ethanol from low to high gradients after rinsing. Finally, xylene was used to make it transparent, and the slices were sealed with neutral resin. The pathological changes of the rat joints were observed under a light microscope. Microscopic examination and image acquisition and analysis were performed.
[0050] 2.6 Statistical methods
[0051] All data are presented as mean ± SD of at least 3 independent experiments. Means were compared using one-way analysis of variance (ANOVA). Results were statistically analyzed using GraphPad Prism Version 9. P < 0.05 was considered statistically significant.
[0052] 3 Results
[0053] 3.1 Preparation of sodium monourate crystals
[0054] After grinding the sodium monourate crystals into powder, the solution was prepared and observed under a microscope. Figure 1 As shown, sodium monourate crystals are distributed in the solution in irregular shapes.
[0055] 3.2 Effects of Wuling Capsule on Joint Circumference and Joint Swelling in Rats with Acute Gouty Arthritis
[0056] After sodium monourate crystal suspension was injected into the ankle joint cavity of rats, the changes in joint circumference and swelling degree of the rats at different time periods were observed. Figure 2 As shown in the data, compared with the blank group, the ankle swelling index of the model group rats increased significantly at 6 and 12 hours after modeling (P<0.01). Compared with the model group, the Wuling capsule groups at various doses had a certain improvement effect on the ankle diameter and joint swelling of rats with acute gouty arthritis. Figure 2 Compared with the blank group: # P<0.05, ## P < 0.001, compared with the model group; * P<0.05, ** P<0.01.
[0057] 3.3 Effect of Wuling Capsule on the Levels of IL-1β and TNF-α in Serum of Rats with Acute Gouty Arthritis
[0058] like Figure 3 As shown in the data, compared with the blank group, the levels of serum inflammatory factors IL-1β and TNF-α in the model group were significantly increased (P<0.05); compared with the model group, the levels of IL-1β and TNF-α decreased after administration of Wuling Capsule at each dose, indicating that Wuling Capsule has the effect of inhibiting the production of inflammatory factors. Figure 3 Compared with the blank group: # P < 0.05, compared with the model group; * P<0.05.
[0059] 3.4 Effect of Wuling Capsule on pain perception in rats with acute gouty arthritis
[0060] The differences in weight distribution of rats in each group were statistically analyzed by bipedal balance pain measurement. Figure 4 As shown in the figure, the difference in weight distribution between the two feet of the rats in the blank group was small, indicating that the difference in weight distribution between the two feet was small. Compared with the blank group, the difference in weight distribution between the two feet of the rats in the model group was large, indicating that the right foot of the rats induced pain due to modeling, resulting in more weight bearing on the left foot. After intervention with different doses of Wuling Capsules, the difference in weight between the two feet of the rats became smaller. Based on this result, it is inferred that Wuling Capsules has a certain effect in relieving pain.
[0061] 3.5 Effect of Wuling Capsule on Ankle Joint Pathology in Rats with Acute Gouty Arthritis
[0062] like Figure 5As shown in the figure, pathological analysis of the ankle joints of rats revealed that the synovial membrane and surrounding tissue cells of the blank group were normal and neatly arranged. After 48 hours of modeling with sodium monourate crystals, the cells in the model group were arranged in disorder, accompanied by inflammatory cell infiltration. After administration of Wuling capsules at various doses, the inflammatory infiltration in the synovium was significantly reduced, and the cells were arranged neatly.
[0063] The above studies show that Wuling Capsule can improve joint swelling in rats with acute gouty arthritis, significantly reduce the level of inflammatory factors in rat serum, relieve pain in rats, and improve the infiltration of inflammatory cells in the synovial tissue of the joints. The above studies have preliminarily confirmed that Wuling Capsule has a certain anti-inflammatory and analgesic effect on rats with acute gouty arthritis.
[0064] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. Application of Wuling Capsule in the preparation of medicines for preventing and treating acute gouty arthritis.
Citation Information
Patent Citations
Chinese composition and preparation method and application thereof
CN101837049A
Traditional Chinese medicinal preparation for treating chronic hepatitis B and preparation method thereof
CN102125630A
Composition of effective Chinese medicine components for treating hepatic fibrosis
CN102188476A
Method for detecting effective components in Wuling capsules
CN111735900A
Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating gouty arthritis
CN116999500A
